Q1 EPS: Vareg Data To Shine At ASCO As Exciting Early-Stage Pipeline Emerges

Research evidence excerpt

Q1 EPS: Vareg Data To Shine At ASCO As Exciting Early-Stage Pipeline Emerges

Biotechnology

Immunome

TD SECURITIES (USA) LLC EARNINGS UPDATE

May 12, 2026

Price: $22.69 (05/12/2026) Q1 EPS: Vareg Data To Shine At ASCO As

Price Target: NA Exciting Early-Stage Pipeline Emerges

BUY (1)

ESG SCORE: 56/100

Tyler Van Buren THE TD COWEN INSIGHT

646 562 1343

Vareg's Phase III data (mPFS HR 0.16) are clearly best-in-class vs Ogsiveo, positioning it to

tyler.vanburen@tdsecurities.com

rapidly take share in DT with a potential launch in 2027. IM-1021 (ROR1 ADC) demonstrated

Nicholas Lorusso early responses in lymphoma with a data presentation by year-end. Three novel ADCs

646 562 1390 with undisclosed targets are progressing, and a Phase I was initiated for 177Lu-FAP RLT,

nick.lorusso@tdsecurities.com

highlighting a rapidly expanding pipeline.

Sam Rollenhagen

212 468 7785 Vareg's Unprecedented 0.16 mPFS HR, 56% ORR, And 83% Median Tumor Volume Reduction

samuel.rollenhagen@tdsecurities.com Support Best-In-Class Profile In DT

Greg W. Torres, Ph.D. Recall, Immunome released Phase III topline data of its small molecule gamma secretase

646 562 1351

inhibitor varegacestat (GSI) in desmoid tumors (DT) in December (note here). Vareg led to

gregory.wiessner@tdsecurities.com

an mPFS hazard ratio (HR) of 0.16 (p<0.0001), outperforming the already impressive 0.29

Key Data benchmark set by Ogsiveo, and doing so under the most stringent assessment criteria (BICR

Symbol NASDAQ: IMNM only, versus clinical and BICR for Ogsiveo; discussed here).

Beta: 2.11

The mPFS data are significant on its own, but the main distinguishing factor lies in the superior

52-Week Range: $26.97-$7.91

quality of responses – including a 56% ORR and an 83% median best reduction in tumor

Market Cap: $2.6B